Dear All
following on from the success of our massive fragment based drug discovery effort targeting the main protease of SARS-CoV-2 which led to the COVID moonshot initiative (https://postera.ai/moonshot/
) and has led to things working out far more than we would have ever imagined in such a short time period (see
https://dndi.org/research-development/portfolio/covid-moonshot/ ) …..
we now have an exciting opportunity to join our team which is part of one of the
NIH/NIAID’s
AViDD centers, namely AI-driven Structure-enabled Antiviral Platform (ASAP)
–So if you are interested in a structure-based drug discovery focused post-doc targeting emerging pathogens of concern then look no further – come and join us at Diamond
– more details here:
closing date: 5th February 2023
don’t hesitate to contact me directly for more details/questions about the post
Martin
—
Martin A. Walsh (He/Him/His),
Deputy Director Life Sciences &
Group Leader at the Research Complex at Harwell,
Diamond Light Source,
Harwell Science & Innovation Campus,
Didcot OX11 0DE,
UK
T:+44 1235 778518
—
This e-mail and any attachments may contain confidential, copyright and or privileged material, and are for the use of the intended addressee only. If you are not the intended addressee or an authorised recipient of the addressee please notify us of receipt by returning the e-mail and do not use, copy, retain, distribute or disclose the information in or attached to the e-mail.
Any opinions expressed within this e-mail are those of the individual and not necessarily of Diamond Light Source Ltd.
Diamond Light Source Ltd. cannot guarantee that this e-mail or any attachments are free from viruses and we cannot accept liability for any damage which you may sustain as a result of software viruses which may be transmitted in or with the message.
Diamond Light Source Limited (company no. 4375679). Registered in England and Wales with its registered office at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom